MedTrace Logo

Six Months DHEA Treatment in Female Adrenal Failure

NCT00471900 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2007-05-10

No results posted yet for this study

Summary

DHEA is an adrenal deriven androgen precourser. The impact of DHEA substitution therapy in adrenal failure is unknown as well as the physiologically effects of DHEA is unknown. Effects of physiologically DHEA substitution is investigated in the model of female adrenal failure.

Conditions

Interventions

DRUG

dehydroepiandrosterone (DHEA)

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jens S Christiansen, Professor · Medical Dept. M, Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Completion
2003-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00471900 on ClinicalTrials.gov